Relapse Prevention in Schizophrenia and Schizoaffective Disorder with Risperidone Long-Acting Injectable vs Quetiapine: Results of a Long-Term, Open-Label, Randomized Clinical Trial
Authors:
- 4 August 2010
- journal article
- research article
- Published by Springer Nature in Neuropsychopharmacology
- Vol. 35 (12) , 2367-2377
Abstract
Chronic management of schizophrenia and schizoaffective disorders is frequently complicated by symptomatic relapse. An open-label, randomized, active-controlled, 2-year trial evaluated 710 patients with schizophrenia or related disorders who were switched from stable treatment with oral risperidone, olanzapine, or conventional neuroleptics to risperidone long-acting injectable (RLAI) or oral quetiapine. Primary effectiveness evaluation was time-to-relapse. Safety evaluations included adverse events (AEs) reported for the duration of the study, Extrapyramidal Symptom Rating Scale (ESRS), clinical laboratory tests, and vital signs. A total of 666 patients (n=329 RLAI, n=337 quetiapine) were evaluable for effectiveness measures. Baseline demographics were similar between treatment groups. Kaplan–Meier estimate of time-to-relapse was significantly longer with RLAI (p<0.0001). Relapse occurred in 16.5% of patients with RLAI and 31.3% with quetiapine. RLAI and quetiapine were both safe and well tolerated. Weight gain affected 7% of patients with RLAI and 6% with quetiapine, with mean end point increases of 1.25±6.61 and 0±6.55 kg, respectively. There were no significant between-group differences in weight gain. ESRS total scores decreased similarly after randomization to either RLAI or quetiapine. Extrapyramidal AEs occurred in 10% of patients with RLAI and 6% with quetiapine. Treatment-emergent potentially prolactin-related AEs were reported in 15 (5%) patients with RLAI and 5 (2%) patients with quetiapine; hyperprolactinemia was reported in 43 (13.1%) patients with RLAI and 5 (1.5%) patients with quetiapine. Somnolence occurred in 2% of patients with RLAI and 11% with quetiapine. To our knowledge, this is the first report of a randomized clinical trial directly comparing relapse prevention with a second-generation long-acting injectable antipsychotic and oral therapy. Time-to-relapse in stable patients with schizophrenia or schizoaffective disorder was significantly longer in patients randomized to RLAI compared with those randomized to oral quetiapine. Both antipsychotics were generally well tolerated.Keywords
This publication has 32 references indexed in Scilit:
- Hyperprolactinemia associated with psychotropics—a reviewHuman Psychopharmacology: Clinical and Experimental, 2010
- A review of the safety and tolerability of aripiprazoleExpert Opinion on Drug Safety, 2009
- Dose trends for second-generation antipsychotic treatment of schizophrenia and bipolar disorderSchizophrenia Research, 2009
- Evaluation of noncompliance in schizophrenia patients using electronic monitoring (MEMS®) and its relationship to sociodemographic, clinical and psychopathological variablesSchizophrenia Research, 2009
- Olanzapine pamoate: a stick in time?International Journal Of Clinical Practice, 2009
- Oral versus injectable antipsychotic treatment in early psychosis: Post hoc comparison of two studiesClinical Therapeutics, 2008
- Somnolence effects of antipsychotic medications and the risk of unintentional injuryPharmacoepidemiology and Drug Safety, 2008
- Cognitive Functioning and Acute Sedative Effects of Risperidone and Quetiapine in Patients With Stable Bipolar I DisorderThe Journal of Clinical Psychiatry, 2007
- The Differentiation between ‘Lack of Insight’ and ‘Dysfunctional Health Beliefs’ in SchizophreniaPsychopathology, 2007
- What does the PANSS mean?Schizophrenia Research, 2005